

Richard Antoni Urbanowicz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3574110/publications.pdf>

Version: 2024-02-01

48
papers

1,651
citations

377584

21
h-index

340414

39
g-index

54
all docs

54
docs citations

54
times ranked

3207
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. <i>Gastroenterology</i> , 2022, 162, 562-574. | 0.6 | 20 |
| 2 | Inflammasome Contribution to the Activation of Th1, Th2, and Th17 Immune Responses. <i>Frontiers in Microbiology</i> , 2022, 13, 851835. | 1.5 | 18 |
| 3 | Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. <i>Molecular Therapy</i> , 2021, 29, 2412-2423. | 3.7 | 41 |
| 4 | The Distribution of Puumala orthohantavirus Genome Variants Correlates with the Regional Landscapes in the Trans-Kama Area of the Republic of Tatarstan. <i>Pathogens</i> , 2021, 10, 1169. | 1.2 | 8 |
| 5 | Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. <i>Science Translational Medicine</i> , 2021, 13, eabj0847. | 5.8 | 40 |
| 6 | Challenges on the development of a pseudotyping assay for Zika glycoproteins. <i>Journal of Medical Microbiology</i> , 2021, 70, . | 0.7 | 5 |
| 7 | Long Term Immune Response Produced by the SputnikV Vaccine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11211. | 1.8 | 9 |
| 8 | Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. <i>Virology Journal</i> , 2020, 17, 140. | 1.4 | 3 |
| 9 | A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice. <i>Vaccine</i> , 2020, 38, 6864-6867. | 1.7 | 7 |
| 10 | A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008459. | 1.3 | 18 |
| 11 | Polymer microarrays rapidly identify competitive adsorbents of virus-like particles. <i>Biointerphases</i> , 2020, 15, 061005. | 0.6 | 5 |
| 12 | Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. <i>Npj Vaccines</i> , 2020, 5, 71. | 2.9 | 21 |
| 13 | Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization. <i>Journal of Virology</i> , 2020, 94, . | 1.5 | 17 |
| 14 | Orthohantaviruses, Emerging Zoonotic Pathogens. <i>Pathogens</i> , 2020, 9, 775. | 1.2 | 22 |
| 15 | The Relationship of the Mechanisms of the Pathogenesis of Multiple Sclerosis and the Expression of Endogenous Retroviruses. <i>Biology</i> , 2020, 9, 464. | 1.3 | 5 |
| 16 | Hepatitis C Virus Vaccine: Challenges and Prospects. <i>Vaccines</i> , 2020, 8, 90. | 2.1 | 53 |
| 17 | Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells. <i>Journal of Virology</i> , 2019, 93, . | 1.5 | 51 |
| 18 | Cloning and Analysis of Authentic Patient-Derived HCV E1/E2 Glycoproteins. <i>Methods in Molecular Biology</i> , 2019, 1911, 275-294. | 0.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp). <i>Methods in Molecular Biology</i> , 2019, 1911, 441-450. | 0.4 | 17 |
| 20 | InFusion Cloning for the Generation of Biologically Relevant HCV Chimeric Molecular Clones. <i>Methods in Molecular Biology</i> , 2019, 1911, 93-104. | 0.4 | 1 |
| 21 | Expression of human ficolin-2 in hepatocytes confers resistance to infection by diverse hepatotropic viruses. <i>Journal of Medical Microbiology</i> , 2019, 68, 642-648. | 0.7 | 4 |
| 22 | Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. <i>Antiviral Research</i> , 2018, 160, 25-37. | 1.9 | 8 |
| 23 | Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?. <i>International Journal of Pharmaceutics</i> , 2018, 547, 572-581. | 2.6 | 29 |
| 24 | A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. <i>Antiviral Research</i> , 2017, 148, 53-64. | 1.9 | 18 |
| 25 | An ancestral host defence peptide within human β -defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule. <i>Scientific Reports</i> , 2016, 5, 18450. | 1.6 | 35 |
| 26 | Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals. <i>Virology</i> , 2016, 492, 213-224. | 1.1 | 3 |
| 27 | Human Adaptation of Ebola Virus during the West African Outbreak. <i>Cell</i> , 2016, 167, 1079-1087.e5. | 13.5 | 180 |
| 28 | A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. <i>Journal of Virology</i> , 2016, 90, 3288-3301. | 1.5 | 62 |
| 29 | Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. <i>Journal of General Virology</i> , 2016, 97, 82-94. | 1.3 | 16 |
| 30 | Flexible and rapid construction of viral chimeras applied to hepatitis C virus. <i>Journal of General Virology</i> , 2016, 97, 2187-2193. | 1.3 | 11 |
| 31 | Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. <i>Journal of General Virology</i> , 2016, 97, 2265-2279. | 1.3 | 33 |
| 32 | Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin. <i>Journal of Peptide Science</i> , 2015, 21, 743-749. | 0.8 | 5 |
| 33 | Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry. <i>Journal of Innate Immunity</i> , 2014, 6, 676-684. | 1.8 | 28 |
| 34 | Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution. <i>Journal of Virology</i> , 2014, 88, 667-678. | 1.5 | 2 |
| 35 | Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation. <i>Journal of Biological Chemistry</i> , 2014, 289, 35015-35028. | 1.6 | 17 |
| 36 | 1178 A NANOBODY RECOGNIZING A NOVEL EPITOPE IN HEPATITIS C VIRUS GLYCOPROTEIN E2 BROADLY NEUTRALIZES VIRUS ENTRY AND INHIBITS CELL-CELL TRANSMISSION. <i>Journal of Hepatology</i> , 2013, 58, S479. | 1.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. <i>Hepatology</i> , 2013, 58, 932-939. | 3.6 | 69 |
| 38 | Differential Activation of Killer Cells in the Circulation and the Lung: A Study of Current Smoking Status and Chronic Obstructive Pulmonary Disease (COPD). <i>PLoS ONE</i> , 2013, 8, e58556. | 1.1 | 34 |
| 39 | The Role of Humoral Innate Immunity in Hepatitis C Virus Infection. <i>Viruses</i> , 2012, 4, 1-27. | 1.5 | 43 |
| 40 | Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization. <i>Journal of Virology</i> , 2012, 86, 2739-2749. | 1.5 | 54 |
| 41 | The role of neutralizing antibodies in hepatitis C virus infection. <i>Journal of General Virology</i> , 2012, 93, 1-19. | 1.3 | 58 |
| 42 | Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype. <i>Journal of Virology</i> , 2011, 85, 4246-4257. | 1.5 | 51 |
| 43 | Quantitative Validation and Comparison of Multiplex Cytokine Kits. <i>Journal of Biomolecular Screening</i> , 2010, 15, 562-568. | 2.6 | 90 |
| 44 | Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients. <i>Respiratory Research</i> , 2010, 11, 76. | 1.4 | 52 |
| 45 | Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2009, 10, 29. | 1.4 | 21 |
| 46 | Altered effector function of peripheral cytotoxic cells in COPD. <i>Respiratory Research</i> , 2009, 10, 53. | 1.4 | 42 |
| 47 | Killer cells in chronic obstructive pulmonary disease. <i>Clinical Science</i> , 2008, 114, 533-541. | 1.8 | 37 |
| 48 | EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE. <i>Drug Metabolism and Disposition</i> , 2004, 32, 1247-1253. | 1.7 | 264 |